Head-to-head evidence
HRS-7535 vs SAL0150
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
HRS-7535
Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals
NCT06672172 · Phase 3 · completed
This is a well-designed randomized, double-blind, placebo-controlled trial with a recognized clinical measure (HbA1c change) as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
SAL0150
Developed by Shenzhen Salubris Pharmaceuticals
NCT05782192 · Phase 3 · completed
The study was randomized, quadruple-masked, and included both active and placebo comparator groups, with 458 participants. Its primary endpoint was the surrogate measure of HbA1c change. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-7535's landscape · SAL0150's landscape